REVENUES (Tables)

3 Months Ended

Mar. 31, 2015

Schedule Of Recognized Net Sales [Table Text Block]

A summary of recognized net sales for the three months ended March 31, 2015 and ending net deferred sales as of March 31, 2015 for the company’s two FDA-approved products as of March 31, 2015 is presented below:

					Deferred Sales
					reclassed against		Ending Deferred
	Sales Recognized in				outstanding		Sales for which
Quarter ended March 31, 2015	the Current Period		Deferred		Accounts		Payment has been
($ in thousands)	(Branded Only)		Sales		Receivable		Collected
Gross Sales	$	74,480	$	35,797	$	(31,954)	$	3,843
Less:
Chargebacks		31,944		-		-		-
Wholesaler distribution fees		6,779		2,946		(2,659)		287
Cash discounts and other		1,491		716		(639)		77
GPO fees and returns		2,098		-		-		-
Net Sales	$	32,168	$	32,135	$	(28,656)	$	3,479

Schedule Of Changes In Reserve Or Liability [Table Text Block]

A summary of changes for each reserve or liability for Bloxiverz^®, Vazculep^™ and the company’s generic pharmaceutical product for the three month period ended March 31, 2015 is as follows:

Quarter ended March 31, 2015							Ending
($ in thousands)	Beginning Balance		Additions		Reductions		Balance
Accounts Receivable Reserves:
Chargebacks	$	1,008	$	37,290	$	(35,116)	$	3,182
Wholesaler distribution fees		1,079		4,185		(3,311)		1,953
Cash Discounts and other		252		2,265		(1,915)		602

Liabilities:
GPO fees		112		1,083		(112)		1,083
Sales returns		234		2,812		(1,801)		1,245

Total	$	2,686	$	47,635	$	(42,256)	$	8,065